Corrigendum: Metabotropic Glutamate Receptor 7: A New Therapeutic Target in Neurodevelopmental Disorders.

[This corrects the article DOI: 10.3389/fnmol.2018.00387.].

In the original article, there was a mistake in Figure 1 as published. The chirality of L-AP4 and LSP1-2111 was incorrect. pEC50 values have also been corrected for LSP1-2111 in Table 1. The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Figure 1

Current tool compounds used to study mGlu7.

Table 1

Summary of current tool compounds used to study mGlu7.

Name (#)	Type	mGlu7 pEC50/pIC50	mGlu8 pEC50/pIC50	mGlu4 pEC50/pIC50	mGlu6 pEC50/pIC50	Source
L-AP4 (1)	Orthosteric agonist	3.47 (PIH)	6.53 (PIH)	7.00 (PIH)	5.62 (PIH)	Acher et al., 2012; Selvam et al., 2018
		3.61 (Ca2+)	6.53 (Ca2+)	6.89 (Ca2+)	6.00 (Ca2+)
LSP4-2022 (2)	Orthosteric agonist	4.34 (Ca2+)	4.54 (Ca2+)	6.96 (Ca2+)	5.36 (Ca2+)	Acher et al., 2012; Goudet et al., 2012; Selvam et al., 2018
LSP1-2111 (3)	Orthosteric agonist	4.28 (PIH)	4.18 (PIH)	5.66 (PIH)	5.77 (PIH)	Selvam et al., 2018
		4.00 (Ca2+)	4.71 (Ca2+)	6.05 (Ca2+)	5.49 (Ca2+)
LSP2-9166 (4)	Orthosteric agonist	5.71 (Ca2+)	4.25 (Ca2+)	7.22 (Ca2+)	not reported	Acher et al., 2012
VU0422288 (5)	Group III PAM	6.85 (Ca2+)	6.93 (Ca2+)	6.98 (Ca2+)	not reported	Jalan-Sakrikar et al., 2014
VU0155094 (6)	Group III PAM	5.80 (Ca2+)	6.07 (Ca2+)	5.48 (Ca2+)	not reported	Jalan-Sakrikar et al., 2014
ADX88178 (7)	mGlu4/8 PAM	>4.52 (Ca2+)	5.66 (Ca2+)	8.46 (Ca2+)	>5	Le Poul et al., 2012
ADX71743 (8)	mGlu7 NAM	7.20 (human, Ca2+)	inactive	inactive	inactive	Kalinichev et al., 2014
		7.06 (rat, Ca2+)	inactive	inactive	inactive
AMN082 (9)	Allosteric agonist	6.59 (GTPγS)	>5 (GTPγS)	>5 (GTPγS)	>5 (GTPγS)	Mitsukawa et al., 2005
XAP044 (10)	Antagonist	5.26 (cAMP)	4.48 (cAMP)	inactive	inactive	Gee et al., 2014
		5.55 to 5.46 (GTPγS)
LY341495 (11)	Orthosteric antagonist	6.00 (cAMP)	6.76 (cAMP)	4.66 (cAMP)	not reported	Kingston et al., 1998
MMPIP (12)	mGlu7 NAM	6.66 (cAMP)	>5 (cAMP)	>5 (cAMP)	not reported	Suzuki et al., 2007
		7.15 (Ca2+)				Niswender et al., 2010
		6.14 (Thallium)				Niswender et al., 2010
VU6010608 (13)	mGlu7 NAM	6.12 (Ca2+)	>5 (Ca2+)	>5 (Ca2+)	inactive (>5)	Reed et al., 2017
VU6005649 (14)	mGlu7/8 PAM	6.19 (Ca2+)	5.59 (Ca2+)	>5 (Ca2+)	inactive	Abe et al., 2017

NAM, negative allosteric modulator; PAM, positive allosteric modulator; EC.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.